Global Subunit Vaccine Market 2022-2028

Global Subunit Vaccine Market 2022-2028

Global Subunit Vaccine Market Size, Share & Trends Analysis Report by Product Type (Protein Antigen, and Polysaccharide Antigen), by Production Type (Denaturing of Proteins, and Genetic Engineering), by Immune Responses Type (Antigen-Presenting Cells (APCs), Cell-Mediated Immunity, Cytokines, Mucosal, and Others), and by Disease (Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others) Forecast Period (2022-2028)

The global subunit vaccine market is anticipated to grow at a significant CAGR of 10.9% during the forecast period. Subunit vaccines work by utilizing a part of a target pathogen to initiate a response from the immune system. Subunit vaccines are manufactured by isolating a specific protein from a pathogen and presenting it as an antigen on its own or they can be manufactured via genetic engineering. The human papillomavirus (HPV) vaccine is a vaccine made using genetic engineering. At present, there are two types of HPV vaccine, one which provides immunity against two strains of HPV, and the other provides immunity against four strains of HPV. The acellular pertussis vaccine and influenza vaccine (in short form) are some other examples of subunit vaccines. Moreover, subunit vaccines are available for hepatitis B (HepB) vaccine, pneumococcal (PCV-7, PCV-10, PCV-13) vaccine, and Haemophilus influenza type b (Hib) vaccine. Subunit vaccines are given to people with weakened immune systems. These vaccines appear to give long-lived immunity since only parts of the virus are used for these vaccines, and the risks of reactions are very low.

Impact of COVID-19 Pandemic on Global Subunit Vaccine Market

At the time of the COVID-19 pandemic, the importance of the immune system rose, which pushed the demand for immune vaccines including subunit vaccinesfor the treatment of COVID-19 patients. Subunit vaccines work by exposing the body to a piece of a pathogen (bacteria, virus, parasite) that causes an immune response, as per the spokesperson from Novavax. The company’s NVX-CoV2373 aspirant vaccine against COVID-19 uses an improved version of the full-length spike (S) protein from SARS-CoV-2 as the subunit antigen. This antigen can’t cause disease but is sent in a way that is read to be acknowledged and learned by the immune system. For its COVID-19 vaccine aspirant, Novavax had a head start owing to its earlier experience while developing vaccines for the original severe acute respiratory syndrome virus and its NanoFlu aspirant for seasonal influenza, as per the company spokesperson. That experience combined with knowledge of the COVID-19 spike protein and access to the company’s nanoparticle technology and proprietary Matrix-M adjuvant helped to accelerate the development of NVC-CoV2373. In July 2021, Novavax began testing a new vaccine aspirant in the pre-clinical environment within weeks of identification of a variant of concern.

Segmental Outlook

The global subunit vaccine market is segmented based on the product type, production type, immune response type,and disease. Based on the product type, the market is segmented into protein antigen and polysaccharide antigen. Based on the production type, the market is segmented into denaturing of proteins, and genetic engineering. Based on the type of the immune response, the market is segmented into antigen-presenting cells (APCs), cell-mediated immunity, cytokines, mucosal, and others. Based on the disease, the market is sub-segmented into infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps, and rubella (MMR), and others. The above-mentioned segments can be customized as per the requirements. Based on product type, protein Antigen is anticipated to hold a prominent share in the market while based on production type, denaturing of proteins segment held a considerable market share during the forecast period.

The Protein Antigen SegmentAnticipated to Hold the Prominent Share in the Global Subunit VaccineMarket

The protein antigen segment is one of the largest segments owing to the availability and adaptability of protein antigen subunit vaccines in the market. Protein subunit vaccines, such as the recombinant hepatitis B vaccine, are made by inserting the genetic code for the antigen into yeast cells, which are relatively easy to grow and capable of synthesizing large amounts of protein. Such advantages gain larger demand among the consumers and users which has been driving the market significantly.

Regional Outlooks

The global subunit vaccine market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).The market can be analyzed for a particular region or country level as per the requirement. The Asia Pacific is anticipated to grow significantly while North America is the leading market for subunit vaccines during the forecast period.

The Asia-Pacific Region is Anticipated to Grow Significantly in the Global Subunit Vaccine Market

Asia-Pacific is projected to grow impressively in the market during the forecast period. One of the core factors is the existing emerging countries such as China, India, Japan, and others which are also the biggest manufacturers and consumers of the pharma industry. China is the biggest raw material for pharma suppliers around the globe. With the rising economy, these countries are boosting their pharma industry including subunit vaccines to fulfill the rising demand for the vaccine.Furthermore, COVID-19 pushed the pharma companies in the region which caused new developments in the subunit vaccines for the treatment. For instance, in March 2021, Gao Fu, the head of China's CDC, led the development of a protein subunit vaccine that was approved by regulators for emergency use, the Chinese Academy of Sciences' Institute of Microbiology informed in a statement.

Market Players Outlook

The major companies serving the global subunit vaccine market include GE Healthcare Life Sciences, GlaxoSmithKline PLC, Merck & Co. Inc., Reber Genetics, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Biological E.,an Indian company,launched the Phase III clinical trial of its Covid-19 subunit vaccine aspirant after gaining the Central Drugs Standard Control Organisation’s (CDSCO) Subject Expert Committee (SEC) approval.

The Report Covers

Market value data analysis of 2021 and forecast to 2028.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global subunit vaccine market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market